P1889
Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine CancerCamrelizumab in Combination With Apatinib Mesylate, Paclitaxel-albumin and S-1 for Translational Treatment of Gastric CancerClinical Study of Apatinib Combined With Temozolomide in the Treatment of Uncontrolled or Repeated High-grade GliomasApatinib for Inoperable Advanced ChondrosarcomaA Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based ChemotherapyConversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Unresectable Gastric CancerPD-1 Antibody (SHR-1210) Plus Apatinib and Capecitabine in Patients With Intrahepatic Cholangiocarcinoma After SurgerySHR-1210 Combined With Apatinib Mesylate in the Perioperative Treatment of Hepatocellular CarcinomaA Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA MutationStudy of Anti-PD-1 Antibody Multimodal Combination as First-line Treatment on Time Window of Advanced Solid TumorA Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBCClinical Study of Albumin-paclitaxel Combined With Apatinib and Camrelizumab in Advanced Gastric CancerA Pharmacokinetic Interaction Study Between Apatinib Mesylate and Transporter Pgp Substrate Digoxin in Advanced Solid Tumor SubjectsPhase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical CarcinomaNeoadjuvant SHR-1210 Plus Apatinib for Resectable Stage III-IV Acral MelanomaStudy to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJCA Food Effect Study of Apatinib Mesylate in Healthy SubjectsEfficacy and Safety of Apatinib Mesylate Tablets Combined With Tegio Capsule for First-line Refractory Patients With Late-stage Gastric CancerA Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.Efficacy and Safety of Camrelizumab for Injection, Apatinib Mesylate and Tegio for First-line Refractory Patients With Advanced Gastric CancerApatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal CarcinomaNeoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung CancerComparison of MAPI+Camrelizumab Versus API+Apatinib Versus MAPI in Patients With a Poor Response to Preoperative Chemotherapy for Newly Diagnosed High-grade OsteosarcomaApatinib Combined With PLD vs PLD for Platinum-resistant Recurrent Ovarian CancerApatinib and Etoposide Capsule Versus Apatinib in Patients With Platinum Resistant Ovarian CancerDrug-drug Interaction Study of Gefitinb on Apatinib in NSCLC PatientsInductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell CarcinomaCamrelizumab Plus Apatinib and Temozolomide as First Line Therapy in Advanced Acral MelanomaCamrelizumab Plus Apatinib and Temozolomide as First Line Therapy in Advanced Acral MelanomaA Study of Sintilimab Combined With Apatinib and Capecitabine in Advanced Hepatocellular CarcinomaThe Combination of Camrelizumab and Apatinib as Second-line Therapy for Advanced Pancreatic CarcinomaA Study to Evaluate the Pharmacokinetics of Apatinib in Subjects With Impaired Renal Function
P4844
Q86246647-378E874C-8F09-4724-B5F8-B1E51FE2F415Q86250604-3C5B4433-5329-4B42-8F12-73492D877836Q86263459-9E851085-2C2B-45FF-B8EA-1C58FBF0933CQ86293992-685B0565-5445-499C-99FC-112902DBD2C5Q86295084-02C47131-A8C3-4D0D-A997-0E1A42EB670FQ86309411-977C00CF-06E0-4985-A970-609329D76053Q87078099-6C15BD31-9342-4535-B0A2-D2D3FC82D701Q87929940-EF2A84B0-4DC2-46F9-A1C2-94F900B278CFQ87930013-40491510-99BB-4BD0-84E3-087B02039DA6Q87930134-422BFC45-F31A-4AB9-B65A-C89011473B8DQ87931338-3EBDB7B8-0916-445D-8095-53EC770E8F6CQ87932953-8E31B23B-4D33-4E2D-AD3A-3ABA075D00C1Q89154594-AE8D53FA-8271-499B-AB87-94C21289E6A3Q89155185-FEF5E04E-F370-436F-A565-2BA8E503A2A9Q89507748-F74453AD-21A8-4E93-BFD8-327527FB8528Q90692553-F3DF48D3-119A-45D9-9515-6529C31B3852Q90693200-D039B763-0FBD-42C2-AB19-C4A024BC90E7Q90693419-F9DF3CA6-0345-4579-BD86-03CB5770260AQ90693703-8F538229-DE27-48E4-93F9-81271996F068Q92191939-E0D6A21C-6932-468B-A927-EDA7990DA826Q92392220-23C79D7F-E7DF-4C63-9B47-78737D562D64Q93581099-F60D8296-1393-4A61-B09D-CCFC53C3A815Q93581691-B71BC4F1-80B7-472B-A215-BDDE242583FEQ93704616-DADDB111-11E6-4BB9-9C2C-202451D2CD7CQ94234776-D0AB9C53-F99F-4949-9F41-98964695848EQ94726251-9B0CD043-34E4-4BD6-AB02-8F5282B906F1Q94934573-E41EE771-D12C-4A84-9D48-24F309BF51F7Q95056527-B93FD877-7909-4445-8EF7-ECBB3A78B789Q95056528-05EE250F-F99B-4FC1-8CC5-9B1BD2B33529Q96055863-5754595D-8406-4CB6-97AC-26A21900862FQ96178924-3C77EC40-265A-48BA-9729-6544DCC59C76Q96178986-E1E039A3-123C-4AF7-9219-58B163A50879
P4844
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Apatinib
@sh
Apatinib
@sr
apatinib
@en
阿帕替尼
@zh
type
label
Apatinib
@sh
Apatinib
@sr
apatinib
@en
阿帕替尼
@zh
altLabel
YN968D1
@en
rivoceranib
@en
prefLabel
Apatinib
@sh
Apatinib
@sr
apatinib
@en
阿帕替尼
@zh
P486
P592
P6366
P661
P662
P2067
P231
811803-05-1
P233
C1CCC(C1)(C#N)C2=CC=C(C=C2)NC(=O)C3=C(N=CC=C3)NCC4=CC=NC=C4
P234
1S/C24H23N5O/c25-17-24(11-1-2- ...... ,11-12,16H2,(H,27,28)(H,29,30)
P235
WPEWQEMJFLWMLV-UHFFFAOYSA-N
P274
P486
P592
CHEMBL3186534
P6366
2780668389
P652
5S371K6132